Audited consolidated financial results for the quarter and year ended 31st March 2025 along with report of statutory auditors.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech posted weak FY25 results on a consolidated basis, with revenue from operations falling about 21.7% to Rs 13,022.84 lakhs (from Rs 16,622.56 lakhs in FY24). The group swung from a profit before tax of Rs 1,097.44 lakhs last year to a loss before tax of Rs (574.35) lakhs, and reported a net loss of Rs (610.75) lakhs versus a profit of Rs 1,042.25 lakhs in FY24. Basic EPS turned negative at Rs (1.35) versus Rs 1.40 a year ago. Q4 FY25 alone saw revenue of Rs 5,056.93 lakhs but a steep loss of Rs (852.59) lakhs. Operating cash flow remained negative at Rs (674.18) lakhs, though better than the Rs (3,035.41) lakhs outflow in FY24. Total borrowings stood at Rs 13,707 lakhs against equity of Rs 9,992 lakhs, and cash balances slipped to Rs 28.82 lakhs. Statutory auditors Venkatesh & Co issued an unmodified (clean) opinion on the consolidated results.
Shareholders face a clear negative event — the group moved from profit to loss, revenue shrank sharply, and leverage is elevated with a debt-to-equity ratio above 1.3x and minimal cash buffer. The stock is likely to see selling pressure, though the clean audit opinion removes any near-term corporate governance overhang.